A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma.
A practicable and selective liquid chromatography-mass spectrometry assay for the determination of two cyclooxygenase-2 inhibitors, etoricoxib and valdecoxib, in human plasma is presented. The analytical technique is based on reversed-phase high-performance liquid chromatography (HPLC) coupled to atmospheric pressure chemical ionisation (APCI) mass spectrometry (Finnigan Mat LCQ ion trap). Mass analysis was performed in the positive ion mode. The ion trap was operated in the tandem MS mode (MS2) and the transitions of etoricoxib (m/z 359.2 --> 280.3) and valdecoxib (m/z 315.1 --> 235.1) were followed by selected reaction monitoring. Retention times of etoricoxib and valdecoxib were 1.05 and 1.08 min, respectively. The method was validated over a linear range 10-2500 and 5-1000 microg/L using the other substrate as internal standard. After validation, the method was used to study the pharmacokinetic pro fi le of etoricoxib or valdecoxib in a healthy volunteer after administration of a single oral dose (valdecoxib, 20 mg; etoricoxib, 90 mg). The presented method was suf fi cient to cover more than 90% of the area under the plasma concentration time curve.
Werner
Ulrike
U
Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany. ulrike.werner@pharmakologie.uni-erlangen.de
Werner
Dierk
D
Hinz
Burkhard
B
Lambrecht
Christoph
C
Brune
Kay
K
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016861:Cyclooxygenase Inhibitors / Q000097:blood*; D000077613:Etoricoxib; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D008297:Male; D013058:Mass Spectrometry / Q000379:methods*; D011725:Pyridines / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D013450:Sulfones / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D000096926:Benzenesulfonamides
D016861:Cyclooxygenase Inhibitors; D000077613:Etoricoxib; D007555:Isoxazoles; D011725:Pyridines; D013449:Sulfonamides; D013450:Sulfones; C406224:valdecoxib; D000096926:Benzenesulfonamides